Phenylalanine and Its Impact on Cognition

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 19, 2019

Primary Completion Date

June 17, 2022

Study Completion Date

June 17, 2022

Conditions
Phenylketonuria
Interventions
DIETARY_SUPPLEMENT

Phenylalanine

The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.

DRUG

Placebo

Placebo capsules are indistinguishable in their appearance from Phe capsules

Trial Locations (1)

3010

Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism (UDEM), Inselspital, Bern University Hospital, Bern

All Listed Sponsors
collaborator

University of Zurich

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03788343 - Phenylalanine and Its Impact on Cognition | Biotech Hunter | Biotech Hunter